Karaarslan Serap, Nur Yurum Fatma, Ebru Pala Emel, Ortac Ragip, Husnu Bugdayci Mehmet
Sifa University Pathology Department, Izmir, Turkey.
Private Ege Pathology Laboratory, Izmir, Turkey.
Pathol Res Pract. 2015 May;211(5):356-60. doi: 10.1016/j.prp.2014.11.007. Epub 2014 Nov 15.
Medullary thyroid carcinoma (MTC) makes up 5-10% of thyroid malignancies. Small cell, squamous, giant cell or melanocytic differentiation can rarely be seen in MTCs. It is important to determine those with the potential to act aggressively such as cases with melanocytic differentiation at the time of diagnosis.
A total of 46 MTC cases diagnosed at four different centers between 2002 and 2013 were included in the study. Immunohistochemical (IHC) staining with Melan-A and HMB-45 was performed in all cases.
Six of the 46 MTC cases were medullary microcarcinomas and three were multicentric medullary carcinomas. There were 34 females and 12 males with a mean age at onset of 51.4 years and mean tumor diameter of 23.2mm. Lymph node metastasis (LNM) was found in 13 of the 38 cases that had data regarding the lymph nodes. Immunohistochemically, Melan A staining was seen in four cases. HMB45 staining was seen in four cases. A statistically significant relationship was found between LNM and diameter, Melan A expression (p=0.02, p=0.03 respectively) but there was no significant relationship with HMB45 expression (p=0.07). General survival data were present for 35 of the 46 cases. All cases without lymph node metastasis survived (21/21) while 8 of 11 cases with lymph node metastasis survived among cases with survival data; one case that was diffuse-strong positive for both HMB45 and Melan A was lost due to distant organ metastasis six months after the diagnosis.
Should the possibility of melanocytic differentiation be evaluated in cases where melanocytic differentiation is not reflected in the morphology (lack of pigment) in MTCs? We did not come across a study on the subject in the English literature. The effect of melanocytic differentiation on the prognosis in MTCs should be investigated in larger series.
甲状腺髓样癌(MTC)占甲状腺恶性肿瘤的5%-10%。小细胞、鳞状、巨细胞或黑色素细胞分化在MTC中很少见。在诊断时确定那些具有侵袭性潜能的病例,如具有黑色素细胞分化的病例很重要。
本研究纳入了2002年至2013年间在四个不同中心诊断的46例MTC病例。所有病例均进行了Melan-A和HMB-45免疫组化(IHC)染色。
46例MTC病例中有6例为髓样微小癌,3例为多中心髓样癌。有34名女性和12名男性,平均发病年龄为51.4岁,平均肿瘤直径为23.2mm。在有淋巴结数据的38例病例中,13例发现有淋巴结转移(LNM)。免疫组化方面,4例可见Melan A染色。4例可见HMB45染色。发现LNM与直径、Melan A表达之间存在统计学显著关系(分别为p=0.02,p=0.03),但与HMB45表达无显著关系(p=0.07)。46例病例中有35例有总体生存数据。所有无淋巴结转移的病例均存活(21/21),而有生存数据的病例中,11例有淋巴结转移的病例中有8例存活;1例HMB45和Melan A均为弥漫强阳性的病例在诊断后6个月因远处器官转移而失访。
在MTC形态学上未体现黑色素细胞分化(缺乏色素)的病例中,是否应评估黑色素细胞分化的可能性?我们在英文文献中未找到关于该主题的研究。黑色素细胞分化对MTC预后的影响应在更大系列中进行研究。